Royalty Pharma sells piece of its interest in J&J cancer drug
This article was originally published in Scrip
Executive Summary
Royalty Pharma sold a piece of its interest in an experimental cancer drug developed by Johnson & Johnson and Pharmacyclics to two venture capital firms.